Center Laboratories - Asset Resilience Ratio
Center Laboratories (4123) has an Asset Resilience Ratio of 3.30% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Center Laboratories's Asset Resilience Ratio has changed over time. Check Center Laboratories PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Center Laboratories's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Center Laboratories (4123) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$852.80 Million | 3.3% |
| Total Liquid Assets | NT$852.80 Million | 3.30% |
Asset Resilience Insights
- Limited Liquidity: Center Laboratories maintains only 3.30% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Center Laboratories Industry Peers by Asset Resilience Ratio
Compare Center Laboratories's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Livzon Pharmaceutical Group Inc
SHE:000513 |
Drug Manufacturers - Specialty & Generic | 2.93% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Canopy Growth Corp
TO:WEED |
Drug Manufacturers - Specialty & Generic | 15.73% |
|
LAVIPHARM S.A. NA EO 1
F:BXA0 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Center Laboratories (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Center Laboratories.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.02% | NT$1.79 Billion ≈ $56.44 Million |
NT$25.54 Billion ≈ $804.56 Million |
-3.53pp |
| 2023-12-31 | 10.54% | NT$2.85 Billion ≈ $89.70 Million |
NT$27.00 Billion ≈ $850.72 Million |
+3.53pp |
| 2022-12-31 | 7.01% | NT$1.77 Billion ≈ $55.65 Million |
NT$25.19 Billion ≈ $793.55 Million |
-8.84pp |
| 2021-12-31 | 15.85% | NT$4.83 Billion ≈ $152.04 Million |
NT$30.44 Billion ≈ $959.14 Million |
+14.97pp |
| 2020-12-31 | 0.88% | NT$244.89 Million ≈ $7.72 Million |
NT$27.87 Billion ≈ $877.97 Million |
-1.31pp |
| 2019-12-31 | 2.19% | NT$499.73 Million ≈ $15.74 Million |
NT$22.87 Billion ≈ $720.38 Million |
+2.11pp |
| 2018-12-31 | 0.08% | NT$16.16 Million ≈ $509.00K |
NT$20.38 Billion ≈ $641.97 Million |
-12.22pp |
| 2017-12-31 | 12.30% | NT$4.71 Billion ≈ $148.38 Million |
NT$38.30 Billion ≈ $1.21 Billion |
-3.92pp |
| 2016-12-31 | 16.22% | NT$4.92 Billion ≈ $155.12 Million |
NT$30.35 Billion ≈ $956.35 Million |
-5.11pp |
| 2015-12-31 | 21.33% | NT$5.95 Billion ≈ $187.59 Million |
NT$27.91 Billion ≈ $879.41 Million |
-0.97pp |
| 2014-12-31 | 22.30% | NT$2.14 Billion ≈ $67.57 Million |
NT$9.62 Billion ≈ $302.96 Million |
-25.12pp |
| 2013-12-31 | 47.43% | NT$2.59 Billion ≈ $81.65 Million |
NT$5.46 Billion ≈ $172.17 Million |
+5.86pp |
| 2012-12-31 | 41.56% | NT$1.69 Billion ≈ $53.39 Million |
NT$4.08 Billion ≈ $128.45 Million |
+27.86pp |
| 2011-12-31 | 13.70% | NT$357.81 Million ≈ $11.27 Million |
NT$2.61 Billion ≈ $82.29 Million |
+0.39pp |
| 2010-12-31 | 13.31% | NT$326.20 Million ≈ $10.28 Million |
NT$2.45 Billion ≈ $77.23 Million |
+5.69pp |
| 2009-12-31 | 7.62% | NT$183.95 Million ≈ $5.80 Million |
NT$2.42 Billion ≈ $76.09 Million |
-8.10pp |
| 2008-12-31 | 15.71% | NT$159.66 Million ≈ $5.03 Million |
NT$1.02 Billion ≈ $32.02 Million |
-11.93pp |
| 2007-12-31 | 27.64% | NT$179.33 Million ≈ $5.65 Million |
NT$648.84 Million ≈ $20.44 Million |
+14.49pp |
| 2006-12-31 | 13.14% | NT$65.14 Million ≈ $2.05 Million |
NT$495.58 Million ≈ $15.61 Million |
-- |
About Center Laboratories
Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretics and analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antituss… Read more